Coegin Pharma: Acquires commercial rights to innovative technology platform - Redeye

Redeye leaves a comment on Coegin Pharma’s announcement of having secured an exclusive agreement with the University of Bradford to acquire the commercial rights to a pioneering patented technology platform with pigmentation peptides. With a possible launch of products already by 2026, we see great potential to expand its cosmetic product offering and increase shareholder value.

Länk till analysen i sin helhet: https://www.redeye.se/research/1027920/coegin-pharma-acquires-commercial-rights-to-innovative-technology-platform?utm_source=finwire&utm_medium=RSS